lobbying_activities: 3335087
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3335087 | 79143d31-44ee-4aba-9a72-6558c921a3ee | Q1 | EMERGENT BIOSOLUTIONS INC. | 304931 | EMERGENT BIOSOLUTIONS INC | 2025 | first_quarter | DIS | Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY25 and FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 920000 | 0 | 0 | 2025-04-15T13:58:13-04:00 |